Skip to main content
. 2023 Nov 7;35:100778. doi: 10.1016/j.lanepe.2023.100778

Fig. 3.

Fig. 3

Temporal trend of therapy sequence of prevalent patients with combined prescriptions of S/V and SGLT2i. COVID-19 = coronavirus disease 2019, ESC = European Society of Cardiology, HF = heart failure, HFrEF = heart failure with reduced ejection fraction, SGLT2i = sodium-glucose co-transporter-2 inhibitor, S/V = sacubitril/valsartan.